

Meningococcal Vaccine

Vaccine Description	<ul style="list-style-type: none"> • Brands: Menomune® and Menactra® • Inactivated, bacterial polysaccharide (Menomune®) • Inactivated, bacterial polysaccharide conjugate (Menactra®) • Contains thimerosal (only multidose Menomune®) and latex (stopper only for Menactra®) • See package insert
Dose & Route	<ul style="list-style-type: none"> • Dose: 0.5 mL • Route: SC (Menomune®) and IM (Menactra®) - (Precaution: hemophilia, thrombocytopenia, and anticoagulation therapy) • See package insert
Indications	<ul style="list-style-type: none"> • U.S. military basic trainees • Children at the 11-12 year of age visit or at subsequent visit • People who might be infected during an outbreak of certain types of meningococcal disease • Anyone traveling to, or living in, a part of the world where meningococcal disease is common, such as sub-Saharan Africa • Anyone who has a non-functioning spleen or whose spleen has been removed • Anyone who has terminal complement component deficiency (an immune system disorder) • People at occupational risk • College freshmen, especially those who live in dormitories • Menactra® is preferred, but is only licensed for use in people between the ages of 2 to 55 years
Administration Schedule	<ul style="list-style-type: none"> • Single dose
Booster	<ul style="list-style-type: none"> • Menomune®: 3-5 years • Menactra®: <ul style="list-style-type: none"> • 5 years if 1st dose given at 7 years of age or older • 3 years if 1st dose given at 2 through 6 years of age